Mid-stage trials are planned for this year.



Implicit Bioscience acquired Eli Lilly’s clinical-stage mAb called IC14 to develop the molecule as a treatment for acute lung injury. Lilly received a combining of cash and stock and will earn a royalty.


Implicit intends to initiate Phase II development this year and recently completed a capital round in which its shareholders added AU$6 million, or $3.9 million, to its cash balance.


“We seek to mitigate product risk through acquiring clinical-stage programs with proven safety and defined opportunities in immunological indications,” explains Garry Redlich, Implicit CEO. “We further mitigate risk by seeking nondilutive third-party funding to support a portion of our development expense.”


Lilly obtained IC14 through its $2.3 billion takeover of Icos. Icos had been investigating the drug in severe sepsis.
Johnson and Johnson, The Scripps Research Institute, The Rockefeller University, and Lilly are parties to a separate agreement with Implicit, which governs the payment to them by Implicit of milestones and royalties on IC14 development and commercialization.








This site uses Akismet to reduce spam. Learn how your comment data is processed.